Utilization of a CYP2C19 genotype-guided antiplatelet treatment algorithm over time in patients undergoing percutaneous coronary intervention by Cervantes, Alexandra
Utilization of a CYP2C19 genotype-guided antiplatelet 
treatment algorithm over time in patients undergoing 
percutaneous coronary intervention 
Alexandra Cervantes, PharmD Candidate 
Faculty Mentor: Craig Lee, PharmD, PhD 
February 5, 2018
		 2	Cervantes	
Abstract 
Purpose: Individuals prescribed clopidogrel that carry a CYP2C19 loss-of-function (LOF) allele 
exhibit higher risk for adverse cardiovascular outcomes following percutaneous coronary 
intervention (PCI). Our institution implemented an algorithm that uses clinical factors 
and CYP2C19 genotype to guide P2Y12 inhibitor selection in high-risk PCI patients.  
Objective: We aimed to evaluate algorithm use over 24 months following implementation in a 
real-world clinical setting.  
Study Design: This single-center, retrospective cohort study included 1193 patients receiving 
coronary stent placement between July 2012-December 2013.  
Methods: Data was abstracted from the electronic health record. CYP2C19 genotype testing, 
P2Y12 inhibitor selection (clopidogrel versus prasugrel/ticagrelor), and changes in anti-platelet 
therapy were compared across 6-month intervals (July-Dec 2012, Jan-Jun 2013, July-Dec 2013) 
by chi-square. 
Results: Overall, a CYP2C19 genotype was obtained in 868 (72.8%) patients 263/868 (30.4%) 
carried a LOF allele, and prasugrel/ticagrelor was prescribed in 186/263 (70.7%) LOF carriers. 
CYP2C19 genotyping testing frequency at index PCI significantly declined over time from 
88.2% (Jul-Dec 2012) to 61.4% (Jan-Jun 2013), 65.1% (Jul-Dec 2013), and 78.1% (Jan-Jun 
2014) (P<0.001). There was also a significant decrease in use of prasugrel/ticagrelor in LOF 
carriers (83% to 78.2% to 53.8%, to 68.1%, respectively, P<0.001). This was accompanied by 
less frequent switching from clopidogrel to prasugrel/ticagrelor in LOF carriers over time 
(P=0.019). No significant difference in prasugrel/ticagrelor selection was observed over time in 
those without a LOF allele (21.3% to 19.9% to 27.4%, to 31.1%, respectively, P=0.348). 
Conclusion: CYP2C19 genotype testing in patients undergoing PCI and conversion to 
prasugrel/ticagrelor in LOF carriers was high over 24 months following implementation of a 
genotype-guided treatment algorithm. However, use of the algorithm in practice appeared to 
decrease over time, as indicated by a decrease in CYP2C19 genotype testing and use of 
prasugrel/ticagrelor in LOF carriers. This suggests that P2Y12 inhibitor selection is complex in 
real-world clinical practice and influenced by multiple factors. 
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Introduction  
 Dual anti-platelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the 
standard of care patients with stable angina and acute coronary syndrome (ACS) undergoing 
percutaneous coronary intervention (PCI) with stent placement.1 Patients receiving stents are at 
increased risk of atherothrombotic events due to the tissue injury that results from stent 
placement and the propensity of platelets to adhere to and aggregate on the surface of coronary 
stents. Currently, there are four FDA approved P2Y12 inhibitors: clopidogrel, prasugrel, 
ticagrelor, and ticlopidine.  
 Although clopidogrel is the most widely used P2Y12 inhibitor in the US, there is 
evidence to suggest that this drug is not an optimal anti-platelet agent for all patients. 
Clopidogrel is a pro-drug that requires hepatic biotransformation via CYP2C19 to its active 
metabolite.2 This particular cytochrome P450 (CYP) enzyme has a loss-of-function (LOF) 
variant allele, CYP2C19*2, with a minor allele frequency in Asians (30%), Caucasian (15%), 
and African-American (17%) populations.3,4 The CYP2C19*2 variant is a 681G>A SNP at the 
junction of intron 4 and exon 5 which causes a splice site change, and consequently premature 
protein translation to yield an inactive protein.4 In addition, a second LOF variant allele, 
CYP2C19*3, is a 636G>A SNP in exon 4 that yields a truncated, inactive protein.3,4 Thus, 
patients carrying either one or two LOF alleles will have lower levels of CYP2C19 function, and 
exhibit a lower capacity to convert clopidogrel to its active metabolite.  Therefore, patients 
carrying one or two CYP2C19 LOF alleles receiving clopidogrel have a higher probability of 
experiencing inadequate inhibition of platelet function, and thus have higher probability of 
experiencing a major adverse cardiovascular events (MACE), such as: stent thrombosis, 
cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke. 
Consequently, CYP2C19 LOF allele carriers that receive clopidogrel following percutaneous 
coronary intervention (PCI) are at higher risk for MACE due to clopidogrel nonresponsiveness,6 
which caused the FDA to issue a black box warning in 2010 to warn against its decreased 
efficacy in CYP2C19 poor metabolizers15. Furthermore, a gain-of-function (GOF) variant allele, 
CYP2C19*17, increases CYP2C19 expression and yields a rapid metabolizer phenotype. This 
allele has a higher minor allele frequency in Caucasians (18%), African-American (18%), and 
Asian (4%) populations.4,5 Theoretically, this GOF allele could enhance clopidogrel’s anti-
platelet effects and clinical efficacy, but it could also increase the risk of adverse bleeding events 
in patients due to increased rate of clopidogrel biotransformation to its active metabolite. 
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However, the association between risk of bleeding and the CYP2C19*17 allele remains unclear, 
as some studies have shown an increase in the risk of bleeding in patients with the GOF allele 
due to enhanced platelet aggregation inhibition,10 while others have shown no significant 
difference.10,11,17 Consequently, the FDA clopidogrel label does not currently comment on the 
CYP2C19*17 GOF allele. 
 In contrast to clopidogrel, the other members of the P2Y12 platelet receptor inhibitor 
class are not impacted by a patient’s CYP2C19 genotype. Furthermore, prasugrel and ticagrelor 
have been shown to significantly reduce the risk of MACE more effectively, compared to 
clopidogrel, in ACS patients undergoing PCI. However, both prasugrel and ticagrelor also 
present an increased risk of bleeding, and have a higher associated cost.7,8 Specifically, in the 
TRITON-TIMI 38 study,12 prasugrel significantly reduced the composite endpoint of death from 
cardiovascular causes, nonfatal MI, or nonfatal stroke compared to clopidogrel. The genotype 
and outcome data from the TRITON-TIMI 38 study was further analyzed in a meta-analysis.15 
This study aimed to assess the association between CYP2C19 genotype and a primary composite 
endpoint of: cardiovascular death, myocardial infarction, and ischemic stroke, in patients treated 
with clopidogrel. Upon pooling genotype and outcome results from nine studies to yield a patient 
population of 9685, carriers of at least one LOF allele were observed to be at a significantly 
increased risk of the composite endpoint, compared to non-carriers, when treated with 
clopidogrel. However, stent thrombosis presented as the adverse cardiovascular effect with the 
highest risk in LOF allele carriers. The PLATO study13 illustrated a similar superiority for 
ticagrelor, as compared to clopidogrel, as ticagrelor reduced the rate of death from vascular 
causes, myocardial infarction, and stroke. A genetic ad hoc analysis of the PLATO study further 
confirmed the superiority of ticagrelor over clopidogrel, irrespective of CYP2C19 genotype.18 
The primary composite outcome of cardiovascular death, myocardial infarction, and stroke was 
consistently reduced in the ticagrelor treatment group, regardless of the presence of a CYP2C19 
LOF allele. However, both prasugrel and ticagrelor demonstrated an increased risk of non-
procedure-related bleeding, compared to clopidogrel, in the TRITON-TIMI 38 study and the 
PLATO study, respectively.11,13 Therefore patients at high-risk of bleeding, may not be 
appropriate candidates for treatment with prasugrel or ticagrelor.  
 Despite the FDA approval of prasugrel and ticagrelor for ACS patients undergoing PCI, 
clopidogrel is still the most widely used P2Y12 inhibitor following PCI for both ACS and non-
ACS indications.16 Current clinical practice guidelines recommend that the choice of P2Y12 
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inhibitor should be based on patient-specific clinical factors and economic considerations. 
Although the guidelines acknowledge the use of CYP2C19 genotyping to guide P2Y12 platelet 
receptor inhibitor selection in high-risk patients,1 the lack of randomized clinical trial data has 
limited the routine implementation of CYP2C19 genetic testing to optimize antiplatelet therapy 
for PCI patients into clinical practice. However, the University of North Carolina (UNC) is one 
of the few institutions that have opted to implement a treatment algorithm that optimizes 
antiplatelet therapy for PCI patients by integrating CYP2C19 genotype and clinical factors to 
guide P2Y12 inhibitor selection. The algorithm recommends alternative P2Y12 inhibitor therapy, 
prasugrel or ticagrelor, for CYP2C19 LOF allele carriers. Initial studies have found that 
personalizing antiplatelet therapy based on genotype is feasible, but the sustainability of this 
practice and its impact on clinical outcomes and cost is uncertain.9 Therefore, the primary 
objective for this study will be to characterize the relationship between CYP2C19 genotype (LOF 
carrier vs. non-carrier), clinical characteristics, and P2Y12 inhibitor selection (clopidogrel vs. 
prasugrel or ticagrelor) in a cohort of patients that had a coronary artery stent placement at UNC. 
 
Methods 
 The utilization of the genotype-guided algorithm was evaluated in a single-center  
retrospective cohort study of patients that underwent PCI with coronary artery stent placement at 
UNC between July 1, 2012 and June 30, 2014. Data was abstracted from the electronic medical 
record for patients that underwent stent placement between July 1, 2013 and June 30, 2014, and 
then this data was combined with previously collected data for patients that had stent placement 
at UNC between July 1, 2012 and June 30, 2013. Baseline data abstracted from the medical 
record included patient demographics, medical history, admission medications, indication for 
PCI, and discharge medications. Patients were then followed in the medical record for 1 year 
after index PCI, in order to collect medication use over time in three follow-up visits. P2Y12 
inhibitor use was collected at admission, discharge, and follow-up.  
CYP2C19 genotyping was performed by UNC McLendon Molecular Genetics 
Laboratory. Genotype results are uploaded into the electronic medical record under the 
‘Molecular Genetics’ laboratory results section. Patient CYP2C19 genotype results were 
abstracted from the electronic medical record, and categorized into the following clopidogrel 
metabolizer phenotypes: ultrarapid (UM; *17/*17), rapid (RM; *1/*17), normal (NM; *1/*1), 
intermediate (IM; *1/*2, *1/*3, *3/*17, *3/*17), or poor (PM; *2/*2, *2/*3, *3/*3). 
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The study population’s demographics, past medical history, admission medications, and 
clinical factors were described using descriptive statistics. Temporal trends in algorithm 
utilization were evaluated using descriptive statistics to compare completion of genotype testing 
(yes versus no), final maintenance P2Y12 inhibitor therapy (clopidogrel versus prasugrel or 
ticagrelor), and changes in anti-platelet therapy from clopidogrel to prasugrel or ticagrelor in 
CYP2C19 LOF allele carriers (yes versus no) over time. Final maintenance P2Y12 inhibitor 
therapy was defined as the P2Y12 inhibitor prescribed to the patient after index PCI and 
CYP2C19 genotyping at the last follow-up visit. Comparisons of these endpoints were made 
across four 6-month periods (July-Dec 2012, Jan-Jun 2013, Jul-Dec 2013, Jan-Jun 2014) by Chi-
square. The study population’s demographic factors, clinical factors, and CYP2C19 phenotype 
status were compared across the primary outcome using a Student’s t-test, Chi-squared test or 
Fisher’s exact test, as appropriate. Associations were evaluated by logistic regression using 
univariate and multivariable models, and the odds ratio (OR) and 95% CIs for each factor were 
calculated. Multivariable models were created using stepwise selection with the criterion of 
p<0.10 to enter the model and p<0.05 to stay in the model. Analyses were performed using SAS-
JMP 12.0 (SAS Institute, NC, USA). P-values <0.05 were considered statistically significant. 
 
Results 
 A total of 1193 patients underwent PCI with stent placement at UNC between July 1, 
2012 and June 30, 2014. The characteristics of the study population are shown in Table 1. The 
mean age was 63.3 years, 807 (67.6%) were male and 819 (68.7%) were Caucasian (Table 1). At 
admission for index PCI, 310 (26%) patients were on a P2Y12 inhibitor, with 266 (85.8%) of 
those patients prescribed clopidogrel. Furthermore, 478 (40.1%) patients had an elevated 
bleeding risk at baseline, as defined by age greater than 75 years, weight less than 60kg, previous 
transient ischemic attack or cerebrovascular attack, previous significant bleeding, end stage renal 
disease, or anticoagulation use.  
 
CYP2C19 Genotype Testing  
 Of the 1193 patients in the study population, 868 (72.8%) underwent CYP2C19 genotype 
testing. Notably, 794 (91.5%) of the genotypes occurred during the index hospital admission, and 
the median time from index PCI to genotype test result was 1 day. Also, the median (IQR) time 
from genotype test order to result was 1 (1-1) day, and 75% of the results were available by the 
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day after PCI. Of the patients that were genotyped, 263 (30.4%) of genotyped patients carried a 
CYP2C19 LOF allele. Specifically, 239 (27.5%) of individuals were classified as IM phenotype 
and 24 (2.8%) of individuals were classified as PM phenotype (Figure 1). 
 
P2Y12 Inhibitor Therapy Selection  
Clopidogrel was the most commonly prescribed P2Y12 inhibitor for maintenance therapy 
(69.4%), with prasugrel (30.6%) and ticagrelor (3.3%) used less frequently. When frequency of 
P2Y12 inhibitors was  assessed across CYP2C19 phenotypes, LOF allele carriers were associated 
with a higher frequency of alternative P2Y12 inhibitor use (70.7%) compared to non-LOF allele 
carriers (26.1%) (p<0.001) (Figure 2B). Specifically, 69.5% of IMs and 83.3% of PMs were 
prescribed alternative therapy. However, clopidogrel use was frequently prescribed in non-LOF 
allele carriers (73.9%) and in patients that were not genotyped (88.9%) (Figure 2A).  
Multiple demographic and clinical factors were significant predictors of 
prasugrel/ticagrelor selection as maintenance therapy in the unadjusted model (Table 2). 
However, the key factors that predicted use of preasugrel/ticagrelor in the multivariable model 
were CYP2C19 IM or PM phenotype status (OR: 12.4; 95% CI: 8.44-18.6; p<0.001), utilization 
of prasugrel or ticagrelor upon admission (OR: 21.3; 95% CI: 6.73-95.0; p<0.001), and ACS 
indication for index PCI (OR: 2.83; 95% CI: 1.93-4.12; p<0.001) (Table 2).  
 
Changes in P2Y12 Inhibitor Therapy 
 A total of 174 (14.6%) patients underwent a change in P2Y12 inhibitor therapy, and most 
of the changes occurred in patients with an available CYP2C19 genotype (94.3%). The 
distribution of P2Y12 inhibitor therapy changes by CYP2C19 phenotype status demonstrated 
that a slight majority occurred in LOF allele carriers (54.3%). A change from clopidogrel to 
prasugrel/ticagrelor most commonly occurred in CYP2C19 LOF allele carriers (90 of 105; 
85.7%), whereas changes from prasugrel/ticagrelor to clopidogrel predominantly occurred in 
CYP2C19 non-LOF allele carriers (57 of 67; 85.1%).	 Therefore, of the 186 (70.7%) CYP2C19 
LOF allele carriers that were prescribed alternative P2Y12 inhibitor therapy, 90 (48.3%) were a 
result of the prescriber changing the patients therapy from clopidogrel to prasugrel or ticagrelor.  
Of these changes in P2Y12 inhibitor therapy in CYP2C19 LOF allele carriers, 43.3% of 
the changes occurred in the inpatient setting during the index PCI admission, with a median 
(IQR) time to change in therapy of 5 (2-15) days (Figure 3). While the median time to change in 
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P2Y12 inhibitor therapy in CYP2C19 non-LOF allele carriers was 14 (2-26) days, and 43.9% of 
these changes occurred in the inpatient setting during the index PCI admission.  
Assessment of Algorithm Sustainability  
The three key markers that were utilized to assess algorithm sustainability were 
frequency of CYP2C19 genotype testing, use of alternative P2Y12 inhibitor therapy in CYP2C19 
LOF allele carriers, and frequency of changing from clopidogrel to an alternative P2Y12 
inhibitor therapy in CYP2C19 LOF allele carriers. The frequency of CYP2C19 genotype testing 
was observed to significantly change over the study period (p<0.001) (Figure 4). A high 
frequency of genotype testing was observed during the initial 6-month period after algorithm 
implementation (88.2%), but then decreased to 61.4%, 65.1%, and 78.1% over the next three 6-
month periods, respectively. However, the frequency of genotype testing results being available 
within 1-day of the index PCI did not significantly change over time (p=0.051), as initially 79% 
of results were returned within 1-day in the first 6-month period, and then was maintained at 
74%, 69%, and 78.4% over the next three 6-month periods, respectively.   
Similar to the CYP2C19 genotype testing results, use of alternative P2Y12 inhibitor 
therapy in CYP2C19 LOF allele carriers significantly changed over time (p=0.001) (Figure 5A). 
Use of alternative P2Y12 inhibitor therapy was initially high in the first 6-month period (83%) 
and was sustained in the second 6-month period (78.2%), but it decreased over time in the next 
two 6-month periods to 53.8% and 68.1%, respectively. However, use of alternative P2Y12 
inhibitor therapy did not significantly change in CYP2C19 non-LOF allele carriers over the study 
period (Figure 4B).  
Finally, changing from clopidogrel to alternative P2Y12 inhibitor therapy significantly 
changed over time in CYP2C19 LOF allele carriers (p=0.019) (Figure 5), but remained relatively 
constant in CYP2C19 non-LOF allele carriers (p=0.536). The first two 6-month periods 
demonstrated a high changing frequency (42.3%-43.6%) from clopidogrel to alternative P2Y12 
inhibitor therapy in CYP2C19 LOF allele carriers, but the frequency of changing subsequently 
decreased during the final two 6-month periods (23.1%-27.8%). However, the proportion of the 
P2Y12 inhibitor changes that occurred in the inpatient setting before discharge in CYP2C19 LOF 
allele carriers and CYP2C19 non-LOF allele carriers did not significantly change over time 
(Figure 7).  
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Discussion 
 With coronary artery disease being the leading cause of morbidity and mortality in the 
United States,14 selection of DAPT agents and duration of therapy have significant influence on 
patient outcomes. Previous studies have demonstrated that implementation of a CYP2C19 
genotype-guided treatment algorithm is feasible.9 However, this study demonstrates that it is 
challenging to sustain genotype-guided algorithm utilization, at a high level, over time. 
Furthermore, this study demonstrates that P2Y12 inhibitor selection is complex in real-world 
clinical practice and is likely influenced by multiple factors, which yields a significant challenge 
to sustaining a genotype-guided algorithm at a high level.  
 Overall there was a high rate of CYP2C19 genotype testing and use of alternative P2Y12 
inhibitor therapy in CYP2C19 LOF allele carriers. However, there were significant fluctuations 
in the frequency of CYP2C19 genotype testing over time. The initial high frequency of genotype 
testing that was observed significantly changed over the subsequent three 6-month periods. 
Furthermore, the initial high proportion of CYP2C19 LOF allele carriers changed from 
clopidogrel to alternative P2Y12 inhibitor therapy significantly changed over time. 
Consequently, prescribing of alternative P2Y12 inhibitor therapy to CYP2C19 LOF allele 
carriers for maintenance therapy significantly changed over time.  
Potential explanations for the fluctuation in algorithm use could include a lack of 
persistent clinician education about genotype-guided P2Y12 inhibitor, minimal prospective data 
in the literature demonstrating outcomes associated with CYP2C19 genotype-guided P2Y12 
inhibitor selection, and a lack of clinical decision support (CDS) within the UNC electronic 
medical record. Notably, the minimal data in the literature demonstrating outcomes associated 
with CYP2C19 genotype-guided P2Y12 inhibitor selection has led to the American College of 
Cardiology Foundation/American Heart Association PCI guidelines designating genetic testing 
and use of alternative therapy in genetically predisposed nonresponders as a practice that “might 
be considered” in high-risk patients (Class IIb, Level of Evidence: C).1 Thus, without key-
opinion leader and guideline support of personalizing P2Y12 inhibitor therapy in PCI patients 
via CYP2C19 genotype testing, prescriber utilization of genetic testing will inevitably be variable 
until more evidence accrues to support changes in practice. Furthermore, the CYP2C19 genotype 
result was available in the laboratory results section of the electronic medical record as a 
molecular genetics report, but CDS was not enabled during the study period. Therefore, unless 
the physician that ordered the CYP2C19 genotype testing looked for the results, the ability to 
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utilize the resulting CYP2C19 genotype testing result is more difficult for prescribers unless a 
CDS alert with genetic testing results triggers, when a P2Y12 inhibitor is ordered. The success of 
pharmacogenomics CDS has been documented in the literature, with CDS recommendations 
being noted to increase the frequency of ordering pharmacogenetics testing and utilization of 
pharmacogenetics testing results to improve patient safety.21-24 In addition, the incorporation of 
clinical pharmacists in inpatient and outpatient settings has been shown to increase utilization of 
pharmacogenetics testing results to optimize prescribing practices.25-26 Throughout the study 
period, inpatient clinical pharmacists were integral in ensuring that CYP2C19 genotype testing 
results were communicated to the prescribing physician if a change in P2Y12 inhibitor therapy 
was recommended. However, if a genotype testing result was returned after a patient was 
discharged, a follow-up telephone call was made to adjust the patient’s therapy as needed. Thus, 
some of the variation in P2Y12 inhibitor changing in CYP2C19 LOF allele carriers may be 
explained by variation in where a patient was in transitions of care. 
 A limitation of this study is the lack of clinical outcome data to demonstrate how variable 
use of the CYP2C19-genotype guided algorithm affected patient cardiovascular outcomes. 
However, emerging data have recently demonstrated that use of alternative P2Y12 inhibitor 
therapy in CYP2C19 LOF allele carriers significantly reduces the risk of major adverse 
cardiovascular events.27 Furthermore, the impact of CYP2C19 genotype-guided P2Y12 
prescribing has been previously studied, and the association of CYP2C19 LOF alleles with poor 
cardiovascular outcomes has been demonstrated in multiple studies. A pre-specified analysis of 
the EXCELSIOR trial, an 800 patient prospective cohort trial, demonstrated that the CYP2C19*2 
allele yielded higher residual platelet reactivity after clopidogrel treatment and this was 
associated with 3.0-fold increase in the incidence of death and myocardial infarction at 1-year 
post-PCI.19 Additionally, the association of CYP2C19*2 genotype was again confirmed by the 
PAPI study, in which carrying a CYP2C19 LOF allele was associated with reduced platelet 
response to clopidogrel treatment and increased risk of a cardiovascular ischemic event or death 
after 1-year of follow-up.20 Therefore, the impact of variable utilization of the CYP2C19 
algorithm that was observed in this study, may lead to poor cardiovascular outcomes for 
CYP2C19 LOF allele carriers.  
Additionally, there are other limitations of this study that need to be acknowledged. First, 
as a retrospective cohort study, prescriber clinical decisions regarding utilization of CYP2C19 
genotype results cannot be confirmed, because there are multiple methods by which a CYP2C19 
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LOF allele carrier might end up on clopidogrel. It is unknown if prescribers made a deliberate 
decision to utilize the CYP2C19 genotype result, or if they may did not referenced the genotype 
result at all in the course of a patient’s care. Furthermore, the data was collected in a 
retrospective manner, which introduces potential error in the manual abstraction of the data. 
Second, the data presented is representative of the experience with genotype-guided P2Y12 
inhibitor selection at a single academic medical center, and the results may not be generalizable 
to other settings and populations. Notably, the patient population in this study was mostly 
Caucasian (68.7%), with just 0.6% of the population identifying as Asian. Thus, utilization of 
this algorithm at institutions that have a larger Asian patient population might require higher 
proportions of prasugrel or ticagrelor use, as the *2 and *3 allele frequencies are higher in this 
race.28 
However, the current study does demonstrate that although use of the genotype-guided 
algorithm was high overall, utilization of the algorithm to guide P2Y12 inhibitor selection was 
difficult to sustain, at a high-level, in real-world clinical practice over time. This may be 
explained by the observed association of clinical factors and CYP2C19 phenotype with P2Y12 
inhibitor selection. Thus, selection of a P2Y12 inhibitor for an individual patient is highly 
complex, and optimal CDS may facilitate prescriber therapy selection. Future studies are 
necessary to determine whether utilization of a CYP2C19 genotype-guided algorithm to select 
P2Y12 inhibitor therapy in clinical practice improves outcomes and reduces cost, and whether 
CDS facilitates higher utilization of the algorithm. 
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Table 1. Study population characteristics 
Characteristic Value 
n 1193 
Age (years) 63.3 ± 11.97 
Sex (male) 807 (67.6%) 
Race (African-American) 247 (20.7%) 
BMI (kg/m2) 29.87 ± 6.4 
   Obese (>30.0kg/m2) 505 (42.3%) 
Current/recent smoker 334 (28.0%) 
History of hypertension 997 (83.6%) 
History of diabetes 496 (41.6%) 
Previous myocardial infarction 325 (27.2%) 
Left ventricular systolic dysfunction (EF<40%) 176 (14.8%) 
Prior revascularization 603 (50.5%) 
Indication for PCI  
   Stable Angina 551 (46.2%) 
   Unstable angina 204 (17.1%) 
   NSTEMI 297 (24.9%) 
   STEMI 141 (11.8%) 
High-risk CADa 976 (81.8%) 
Multivessel diseaseb 152 (12.7%) 
Drug-eluting stent 1004 (84.2%) 
Elevated bleeding riskc 478 (40.1%) 
Medication use at discharge  
   Aspirin 1173 (98.3%) 
   ACE inhibitor or ARB 801 (67.1%) 
   Beta-blocker 1009 (84.6%) 
   Statin 1123 (94.1%) 
   Proton pump inhibitor 371 (31.1%) 
a. Defined as either an acute coronary syndrome or stable coronary disease with high-risk anatomy findings 
b. Defined as coronary artery disease in >2 coronary arteries or isolated left main disease 
c. Defined as one or more of the following: age>75 years; previous TIA/CVA; anticoagulant prescribed at discharge; history of alcohol 
abuse; current stage 5 chronic kidney disease; previous significant bleeding event; current severe hepatic dysfunction. 
ACE: angiotensin-converting enzyme; ARB: Angiotensin receptor blocker; CVA: Cerebrovascular accident; EF: Ejection fraction; NSTEMI: 
Non-ST elevation myocardial infarction; STEMI: ST elevation myocardial infarction; TIA: Transient ischemic attack 
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Table 2. Predictors of P2Y12 inhibitor maintenance therapy following the index PCI 
Variable Clopidogrel (n=539) 
Prasugrel/ 
Ticagrelor 
(n=329) 
OR 
(95%CI) p-value 
Adjusted 
OR 
(95% CI) 
p-value 
n 828 (69.4%) 365 (30.6%)     
Age 65.0±12.1 59.6±10.8 0.96 (0.95-0.97) <0.001 0.98 (0.96-0.99) 0.007 
Male 530 (64.0%) 277 (75.9%) 1.77 (1.34-2.35) <0.001   
African American 186 (22.5%) 61 (16.7%) 0.69 (0.50-0.95) 0.022   
Obese 336 (40.6%) 169 (46.3%) 1.26 (0.98-1.62) 0.066   
Current/recent 
smoker 225 (27.2%) 109 (29.9%) 
1.14 
(0.87-1.50) 0.342   
Hypertension 725 (87.6%) 272 (74.5%) 0.42 (0.30-0.57) <0.001 
0.50  
(0.33-0.76) 0.001 
Diabetes 376 (45.4%) 120 (32.9%) 0.59 (0.46-0.76) <0.001   
Peripheral vascular 
disease 115 (13.9%) 32 (8.8%) 
0.60 
(0.39-0.89) 0.011   
Atrial fibrillation 91 (11.0%) 18 (4.9%) 0.42 (0.24-0.69) <0.001   
Heart failure 146 (17.6%) 45 (12.3%) 0.66 (0.45-0.93) 0.019   
Previous myocardial 
infarction 234 (28.3%) 91 (24.9%) 
0.84 
(0.63-1.11) 0.232   
Elevated bleeding 
riska 385 (46.5%) 93 (25.5%) 
0.39 
(0.30-0.51) <0.001   
Previous coronary 
artery stent 355 (43.9%) 111 (30.4%) 
0.58 
(0.45-0.76) <0.001   
Clopidogrel use on 
admission 231 (27.9%) 35 (9.6%) 
0.27 
(0.18-0.40) <0.001 
0.29  
(0.17-0.47) <0.001 
Prasugrel/Ticagrelor 
use on admission 6 (0.7%) 38 (10.4%) 
15.9 
(7.18-42.2) <0.001 
18.5  
(5.75-84.4) <0.001 
Index PCI       
   Acute coronary 
syndrome 399 (48.2%) 243 (66.6%) 
2.14 
(1.66-2.77) <0.001 
2.80  
(1.93-4.12) <0.001 
   LAD artery stent 318 (38.4%) 179 (49.0%) 1.54 (1.20-1.98) 0.001 
1.64  
(1.16-2.34) 0.005 
   Left main artery 
stent 22 (2.7%) 8 (2.2%) 
0.82 
(0.34-1.79) 0.985   
   Drug-eluting stent 689 (83.2%) 315 (86.3%) 1.27 (0.90-1.82) 0.173   
CYP2C19 genotype 
available 539 (65.1%) 329 (90.1%) 
4.90 
(3.41-7.22) <0.001   
CYP2C19 IM or PM 
phenotype 77 9.3%) 186 (51.0%) 
7.80 
(5.66-10.9) <0.001 
13.1  
(8.84-19.7) <0.001 
a. Elevated bleeding risk is a composite variable defined as one or more of the following: age>75 years; weight <60kg; previous TIA or 
stoke event; previous significant bleeding event; end stage renal disease requiring dialysis; anticoagulant prescribed at discharge 
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Figure 1. CYP2C19 Phenotype Frequencies. CYP2C19 phenotype distribution in genotyped 
patients: ultrarapid (UM: n=40; 4.6%), rapid (RM: n=196; 22.6%), normal (NM: n=369; 42.5%), 
intermediate (IM: n=239; 27.5%); poor (PM: n=24; 2.8%) metabolizers. 
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Figure 2. P2Y12 inhibitor maintenance therapy selection by CYP2C19 phenotype. 
Maintenance therapy distribution (clopidogrel, or prasugrel/ticagrelor) by CYP2C19 phenotype. 
The frequency of alternative P2Y12 therapy is compared between IM/PMs and NM/RM/UMs 
(B), and the chi-squared p-value is provided. 
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Figure 3. Time to P2Y12 inhibitor change in IM/PMs. Time to P2Y12 inhibitor change was 
calculated from the index PCI date.  
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Figure 4. CYP2C19 genotype testing over time. The index PCI date was categorized into 6-
month periods. Current genotype is defined as a CYP2C19 genotype test ordered at the time of 
index PCI, and old genotype is defined as a CYP2C19 genotype test ordered before the index 
PCI. The frequency of an available CYP2C19 genotype (old and current genotypes combined) 
was compared across time periods. The chi-squared p-value is provided. 
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Figure 5. Final maintenance P2Y12 inhibitor selection by CYP2C19 phenotypes over time. 
The index PCI date was categorized into 6-month periods. The frequency of alternative P2Y12 
therapy (prasugrel or ticagrelor) use in the (A) CYP2C19 IM/PM and (B) CYP2C19 
NM/RM/UM were compared across time periods. The chi-squared p-value is provided.  
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Figure 6. P2Y12 inhibitor change frequency by CYP2C19 phenotypes over time. The index PCI was 
categorized into 6-month intervals. The frequency of changing from clopidogrel to alternative P2Y12 
therapy (prasugrel or ticagrelor) in CYP2C19 IM/PM (A) and CYP2C19 NM/RM/UM (B) were 
compared across time periods. The chi-squared p-value is provided for clopidogrel to prasugrel/ticagrelor 
in IM/PM (6A), and for prasugrel/ticagrelor to clopidogrel in NM/RM/UM (6B). 
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Figure 7. Proportion of P2Y12 inhibitor changes occurring in the inpatient setting over 
time. The proportion of inpatient clopidogrel to prasugrel/ticagrelor changes during the index 
PCI admission for CYP2C19 IM/PM (A) and prasugrel/ticagrelor to clopidogrel changes for 
CYP2C19 NM/RM/UM (B) were compared across time periods. The chi-squared p-values are 
provided.	 
54.8%
37.5% 33.3% 35.0%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2012 (JUL-DEC)
N=31
2013 (JAN-JUN)
N=24
2013 (JUL-DEC)
N=15
2014 (JAN-JUN)
N=20
62.5%
47.1%
25.0%
33.3%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2012 (JUL-DEC)
N=16
2013 (JAN-JUN)
N=17
2013 (JUL-DEC)
N=12
2014 (JAN-JUN)
N=12
P=0.195
P=0.299
		 21	Cervantes	
References: 
1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for 
Percutaneous Coronary Intervention. A report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines and the Society for 
Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122. 
2. Plosker GL, Lyseng-williamson KA. Clopidogrel: a review of its use in the prevention of 
thrombosis. Drugs. 2007;67(4):613-46. 
3. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug 
disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-50. 
4. Ellis KJ, Stouffer GA, Mcleod HL, Lee CR. Clopidogrel pharmacogenomics and risk of 
inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 
2009;10(11):1799-817. 
5. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes 
ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and 
antidepressants. Clin Pharmacol Ther. 2006;79(1):103-13. 
6. Snoep JD, Hovens MM, Eikenboom JC, Van der bom JG, Jukema JW, Huisman MV. 
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with 
stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221-31. 
7. Wiviott SD, Braunwald E, Mccabe CH, et al. Prasugrel versus clopidogrel in patients with 
acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. 
8. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute 
coronary syndromes. N Engl J Med. 2009;361(11):1045-57. 
9. Lee JA, Lee CR, Reed BN, et al. Implementation and evaluation of a CYP2C19 genotype-
guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. 
Pharmacogenomics. 2015;16(4):303-13. 
10. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet 
aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary 
stent placement. Circulation. 2010;121(4):512-8. 
11. Bauer T, Bouman HJ, Van werkum JW, Ford NF, Ten berg JM, Taubert D. Impact of 
CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: 
systematic review and meta-analysis. BMJ. 2011;343:d4588. 
		 22	Cervantes	
12. Wiviott SD, Braunwald E, Mccabe CH, et al. Prasugrel versus clopidogrel in patients with 
acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. 
13. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute 
coronary syndromes. N Engl J Med. 2009;361(11):1045-57. 
14. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a 
report from the American Heart Association. Circulation. 2015;131(4):e29-322. 
15. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of 
adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a 
meta-analysis. JAMA. 2010;304(16):1821-30. 
16. Sherwood MW, Wiviott SD, Peng SA, et al. Early clopidogrel versus prasugrel use among 
contemporary STEMI and NSTEMI patients in the US: insights from the National 
Cardiovascular Data Registry. J Am Heart Assoc. 2014;3(2):e000849. 
17. Simon T, Verstuyft C, Mary-krause M, et al. Genetic determinants of response to clopidogrel 
and cardiovascular events. N Engl J Med. 2009;360(4):363-75. 
18. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide 
polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary 
syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320-8. 
19. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism 
and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of 
elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll 
Cardiol. 2008;51(20):1925-34. 
20. Shuldiner AR, O'connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 
genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 
2009;302(8):849-57. 
21. O'donnell PH, Wadhwa N, Danahey K, et al. Pharmacogenomics-Based Point-of-Care 
Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 
2017;102(5):859-869. 
22. Caraballo PJ, Bielinski SJ, St sauver JL, Weinshilboum RM. Electronic Medical Record-
Integrated Pharmacogenomics and Related Clinical Decision Support Concepts. Clin Pharmacol 
Ther. 2017;102(2):254-264. 
23. Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. Clinical 
impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home 
		 23	Cervantes	
health patients: A prospective pilot randomized controlled trial. PLoS ONE. 
2017;12(2):e0170905. 
24. Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating 
pharmacogenomics into electronic health records with clinical decision support. Am J Health 
Syst Pharm. 2016;73(23):1967-1976. 
25.	 Hicks JK, Stowe D, Willner MA, et al. Implementation of Clinical Pharmacogenomics within 
a Large Health System: From Electronic Health Record Decision Support to Consultation 
Services. Pharmacotherapy. 2016;36(8):940-8. 
26.	 Caraballo PJ, Hodge LS, Bielinski SJ, et al. Multidisciplinary model to implement 
pharmacogenomics at the point of care. Genet Med. 2017;19(4):421-429. 
27. Cavallari LH, Lee CR, Beitelshees AL, et al. Multisite Investigation of Outcomes 
With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous 
Coronary Intervention. JACC Cardiovasc Interv. 2017; 
28. Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation 
Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. 
Pharmacol. Ther. 94(3), 317–323 (2013). 
  
		 24	Cervantes	
Acknowledgements 
 First, I would like to acknowledge my advisor, Dr. Craig Lee, who provided mentorship 
and guidance throughout my work on this project, and mentorship to a series of fellows and 
student pharmacists that preceded me on this project and assisted with data collection. Notably, 
Dr. John Andrew Lee, Dr. Melissa Polasek, Nicholas Varunok, Dr. Kasey Hamrick, and Dr. 
Vindhya Sriramoju significantly contributed to data collection efforts. In addition, I would like to 
acknowledge Dr. Lucius Howell and Dr. Shivanshu Madan who supported this project by 
verifying select collected data. Dr. Megan Clarke and Dr. Jonathan Cicci provided pharmacy 
support for the CYP2C19 algorithm by following up with pharmacotherapy recommendations 
for CYP2C19 genotype testing results. Dr. Karen Weck from the UNC Department of Pathology 
and Laboratory Medicine assisted with running the CYP2C19 genotype testing samples and 
inputting results into the electronic medical record. Finally, I would like to acknowledge Dr. 
George Stouffer who has provided guidance for this project and substantial support for the 
implementation of the CYP2C19 genotype-guided algorithm at UNC Medical Center. 
 
 
